Large scale chromatographic purification of alpha 1-antitrypsin from human plasma supernatant II + III.

T. Burnouf, J. Constans, A. Clerc, J. Descamps, L. Martinache, M. Goudemand

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We describe a large-scale chromatographic method to purify alpha 1-antitrypsin (AAT) from human plasma supernatant II + III. Supernatant II + III was injected onto DEAE sepharose CL 6B to get an albumin-rich fraction as well as a fraction that contained about 45% AAT. This intermediate purity AAT fraction was further purified by size-exclusion chromatography on Sephacryl S-200. The product was heated in solution at 60 degrees C for 10 hours in the presence of a stabilizer to lower the risk of transmission of viral diseases. Purity of the AAT concentrate is over 85%; clinical testing of its safety and efficacy in the treatment of PiZ patients is underway.

Original languageEnglish
Pages (from-to)31-38
Number of pages8
JournalDevelopments in Biological Standardization
Volume67
Publication statusPublished - 1987
Externally publishedYes

Fingerprint

alpha 1-Antitrypsin
Virus Diseases
Gel Chromatography
Albumins
Safety

ASJC Scopus subject areas

  • Biotechnology

Cite this

Large scale chromatographic purification of alpha 1-antitrypsin from human plasma supernatant II + III. / Burnouf, T.; Constans, J.; Clerc, A.; Descamps, J.; Martinache, L.; Goudemand, M.

In: Developments in Biological Standardization, Vol. 67, 1987, p. 31-38.

Research output: Contribution to journalArticle

Burnouf, T. ; Constans, J. ; Clerc, A. ; Descamps, J. ; Martinache, L. ; Goudemand, M. / Large scale chromatographic purification of alpha 1-antitrypsin from human plasma supernatant II + III. In: Developments in Biological Standardization. 1987 ; Vol. 67. pp. 31-38.
@article{edb5dc13c1124646957f1636bc51f8b5,
title = "Large scale chromatographic purification of alpha 1-antitrypsin from human plasma supernatant II + III.",
abstract = "We describe a large-scale chromatographic method to purify alpha 1-antitrypsin (AAT) from human plasma supernatant II + III. Supernatant II + III was injected onto DEAE sepharose CL 6B to get an albumin-rich fraction as well as a fraction that contained about 45{\%} AAT. This intermediate purity AAT fraction was further purified by size-exclusion chromatography on Sephacryl S-200. The product was heated in solution at 60 degrees C for 10 hours in the presence of a stabilizer to lower the risk of transmission of viral diseases. Purity of the AAT concentrate is over 85{\%}; clinical testing of its safety and efficacy in the treatment of PiZ patients is underway.",
author = "T. Burnouf and J. Constans and A. Clerc and J. Descamps and L. Martinache and M. Goudemand",
year = "1987",
language = "English",
volume = "67",
pages = "31--38",
journal = "Developments in Biological Standardization",
issn = "0301-5149",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Large scale chromatographic purification of alpha 1-antitrypsin from human plasma supernatant II + III.

AU - Burnouf, T.

AU - Constans, J.

AU - Clerc, A.

AU - Descamps, J.

AU - Martinache, L.

AU - Goudemand, M.

PY - 1987

Y1 - 1987

N2 - We describe a large-scale chromatographic method to purify alpha 1-antitrypsin (AAT) from human plasma supernatant II + III. Supernatant II + III was injected onto DEAE sepharose CL 6B to get an albumin-rich fraction as well as a fraction that contained about 45% AAT. This intermediate purity AAT fraction was further purified by size-exclusion chromatography on Sephacryl S-200. The product was heated in solution at 60 degrees C for 10 hours in the presence of a stabilizer to lower the risk of transmission of viral diseases. Purity of the AAT concentrate is over 85%; clinical testing of its safety and efficacy in the treatment of PiZ patients is underway.

AB - We describe a large-scale chromatographic method to purify alpha 1-antitrypsin (AAT) from human plasma supernatant II + III. Supernatant II + III was injected onto DEAE sepharose CL 6B to get an albumin-rich fraction as well as a fraction that contained about 45% AAT. This intermediate purity AAT fraction was further purified by size-exclusion chromatography on Sephacryl S-200. The product was heated in solution at 60 degrees C for 10 hours in the presence of a stabilizer to lower the risk of transmission of viral diseases. Purity of the AAT concentrate is over 85%; clinical testing of its safety and efficacy in the treatment of PiZ patients is underway.

UR - http://www.scopus.com/inward/record.url?scp=0023067448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023067448&partnerID=8YFLogxK

M3 - Article

C2 - 3497064

AN - SCOPUS:0023067448

VL - 67

SP - 31

EP - 38

JO - Developments in Biological Standardization

JF - Developments in Biological Standardization

SN - 0301-5149

ER -